Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 5Uterine Cervical Neoplasms 2Sarcoma 2Oropharyngeal Neoplasms 2Lung Neoplasms 2Hodgkin Disease 2Cholangiocarcinoma 2Carcinoma, Hepatocellular 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Rhabdoid Tumor 1Rectal Neoplasms 1Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma 1Ovarian Neoplasms 1Neoplasms 1Multiple Myeloma 1Mesothelioma 1Melanoma 1Lymphoma, Mantle-Cell 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Leukemia, Plasma Cell 1HIV Infections 1Disease 1Chordoma 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

prednylidene 1etoposide phosphate 1deltacortene 1Vincristine 1Vinblastine 1Specimen Handling 1Procarbazine 1Prednisone 1Prednisolone 1Nivolumab 1Methylprednisolone 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Etoposide 1Doxorubicin 1Dacarbazine 1Cyclophosphamide 1Brentuximab Vedotin 1Bleomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 × Fluorodeoxyglucose F18 × 30 days × Clear all
NCT05675410 2026-06-03

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

National Cancer Institute (NCI)

Phase 3 Recruiting
1,875 enrolled
Lymphoid

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡